ArticleDiscover oncology2026
Targeting macrophage-associated core genes for prognostic prediction and therapeutic insights in bladder cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aims at investigating the function of macrophage-related genes (MRGs) within the bladder cancer immune microenvironment and exploring their potential value in prognosis prediction and therapeutic decision-making.
methodThis study integrated bladder cancer transcriptomic data from the TCGA and GEO databases along with single-cell RNA sequencing (scRNA-seq) data to systematically identify key MRGs. Differential expression analysis, weighted gene co-expression network analysis (WGCNA), and single-cell sequencing analysis served for screening for core MRGs. The results from LASSO Cox regression analysis were used for constructing a survival risk prediction model, together with the evaluation of the model's predictive accuracy. Besides, core MRGs were subjected to immune cell infiltration and drug sensitivity analyses for the elucidation of their roles in immune regulation and therapeutic response. Furthermore, key genes in the prognostic model were validated using PCR, Western blot, and immunohistochemistry.
resultThis study identified 11 core genes significantly associated with macrophages and developed a risk prediction model based on ANXA1, ST3GAL5, and VIM. The model demonstrated moderate predictive performance across all samples (AUC = 0.682), indicating potential utility for patient stratification. Immune analysis revealed that high-risk patients exhibited a distinctly immunosuppressive tumor microenvironment (TME), characterized by increased infiltration of M2 macrophages and neutrophils, along with a significant reduction in effector immune cells of CD8⁺ T cells and NK cells. Additionally, high-risk patients displayed greater sensitivity to targeted therapies but reduced sensitivity to conventional chemotherapy. According to in vitro and in vivo experiments, ST3GAL5 overexpression significantly promoted bladder cancer cell proliferation and tumor growth, underscoring its potential role in tumor progression.
conclusionThis study highlights the crucial impact of MRGs on the TME of bladder cancer and constructs a risk prediction model with moderate predictive performance that may assist in patient stratification, although further validation in independent cohorts is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.